Wyatt Technology Publishes Whitepaper on Protein Quality Control in High-Throughput Screening Studies
Wyatt Technology has published a new whitepaper outlining how to evaluate the solution quality of biotherapeutic candidates prior to screening via Surface Plasmon Resonance (SPR) or Bio Layer Interferometry (BLI). The DynaPro Plate Reader II. Analyte quality is critical to obtaining accurate and
meaningful measurements to select the most promising therapeutic candidates, so ensuring the quality of samples is a vital step in the screening process. The DynaPro highthroughput dynamic light scattering (HT-DLS) system provides an effective method of assessing sample materials using a non-invasive, non-pertubative optical technique.
SPR and BLI are popular techniques for high-throughput screening and discovery of biotherapeutic candidates. Impurities such as aggregates and foreign particles often affect measurements through noise, spurious signals and inaccurate active concentrations. In addition, owing to their size and the small apertures of the on-chip channels, particulates may cause blockage to occur in sensitive SPR microfluidics.
Dr Daniel Some, Principal Scientist at Wyatt Technology, commented: “Guaranteeing that samples are appropriate for SPR, BLI or ITC analyses is critical to proper binding screens. The rapid and automated quality assessment provided by the DynaPro Plate Reader II HT-DLS system ensures a valuable layer of quality control that would simply not be an option with manual, cuvette-based testing. When single binding experiments are needed, the DynaPro NanoStar microcuvette DLS system evaluates solution quality with as little as one microliter of sample.”
Requiring no fluidic handling, the DynaPro Plate Reader II HT-DLS system can quickly and effectively analyze protein quality in large sample populations with no concerns for carryover between samples. By automatically classifying samples as high, medium, and low quality, the DynaPro, in conjunction with DYNAMICS
data analysis, collection, and reporting software, provides intuitive visual analysis to quickly evaluate the suitability of each solution for reliable binding screens.
The DynaPro performs measurements in the same microwell plates as SPR and BLI highthroughput discovery screening platforms, saving researchers considerable time and effort in assessing the quality of large batches of biotherapeutic samples and ensuring accurate results. By presenting several example analyses, the whitepaper showcases the HT-DLS process and DYNAMICS visualizations that make quality control with the DynaPro system practically effortless
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.